富瑞:對蒙牛(2319.HK)長期增長持正面態度 重申買入評級
富瑞發表研究報吿指,妙可藍多以每股29.71元人民幣的價格向蒙牛乳業(2319.HK)發行1.01億股非公開發行股票,有關申請已獲中證監批准。交易完成後,蒙牛將成妙可藍多的控股股東,持股比例為27.5%。富瑞維持蒙牛目標價58港元,重申買入評級。
富瑞表示,完成有關交易後,蒙牛將在未來兩年內,將其現有的奶酪業務投入至妙可藍多。通過在原材料、生產技術、渠道分銷和營運管理等方面的合作,該行看到擴大銷售、提高毛利率和節省開支的巨大潛力。
該行指出,考慮到芝士類別的快速增長和交易的協同作用,認為收購價格屬合理,並指對蒙牛的長期增長持正面態度。

Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.